Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection

Status Recruiting

Clinical Trial Summary

Liver resection is an operation to remove the diseased part of the liver. The liver is supplied by two vessels, the hepatic artery and the portal vein supplying 25% and 75% respectively of the total blood flow with 50% oxygen from each vessel. During liver resection it is standard practice to clamp both vessels(Pringle's manoeuvre), so as to avoid bleeding. Clamping both the vessels deprives the unaffected liver from nutrients required for survival. Reinstating the blood supply causes further damage by pouring harmful substances into the liver, which accumulate during the clamping. We hypothesize that not clamping the oxygen rich hepatic artery will cause less damage to the liver.

Our aim is to compare the Pringle manoeuvre with portal vein clamping, to identify if the latter will result in less tissue injury and thereby fewer complications. Initially we aim to conduct a pilot study. The main objective is to ensure that patients can be successfully recruited and that data capture is complete. The secondary outcomes will be development of infective complications by 30 days following surgery, bleeding and blood transfusion requirements, heart/chest complications, recovery of liver functions, growth of remnant liver, death within 30 days following surgery, length of high dependency unit/hospital stay and quality of life at 3 months after surgery.

There is published literature on the safety of this method and in the event of any intraoperative problems, the procedure will be converted to the standard Pringle manoeuvre. The Liver Unit at St James's University Hospital has four surgeons performing around 270 liver cancer resections per year, of which nearly 160 are for bowel cancer spread. Considering the team's experience in research and liver surgery, we believe it is well placed to conduct the trial in a safe and efficient manner.

Clinical Trial Description

n/a

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02042794
Study type	Observational
Source	The Leeds Teaching Hospitals NHS Trust
Contact	Raj Prasad
Email	raj.prasad@leedsth.nhs.uk
Status	Recruiting
Phase	N/A
Start date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05524155` - Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis	Phase 2
Recruiting	`NCT02632201` - Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis	Phase 1/Phase 2
Enrolling by invitation	`NCT01715402` - Optimization of Health Expenditure in Liver Surgery	N/A
Recruiting	`NCT01035385` - Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)	Phase 3
Recruiting	`NCT05098847` - Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors	Phase 2
Withdrawn	`NCT02651090` - Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI	Phase 3
Withdrawn	`NCT01775280` - Response of Hepatic Tumors to Radioembolization	Phase 2
Completed	`NCT00068068` - Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases	Phase 2
Terminated	`NCT02453490` - Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis	Phase 3
Recruiting	`NCT04622423` - Advanced Therapies for Liver Metastases
Completed	`NCT00892424` - Sorafenib-RT Treatment for Liver Metastasis (SLIM)	Phase 1/Phase 2
Completed	`NCT00028405` - Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors	Phase 1
Completed	`NCT03801915` - Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers	Phase 2
Completed	`NCT02218801` - A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
Completed	`NCT01834014` - Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases	N/A
Completed	`NCT00083785` - Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases	Phase 2
Active, not recruiting	`NCT03428477` - EPA for Metastasis Trial 2	Phase 3
Completed	`NCT02316028` - Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)	Phase 1/Phase 2
Completed	`NCT01785212` - The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver	N/A
Completed	`NCT03785210` - Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers	Phase 2